Copyright
©The Author(s) 2021.
World J Diabetes. Dec 15, 2021; 12(12): 2087-2095
Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2087
Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2087
Figure 2 Maximum changes in hemoglobin A1c from baseline in the subgroups after omarigliptin administration.
The Kruskal-Wallis test was used to determine the differences and degree of significance (P < 0.05). AO: Add-on; HbA1c: Hemoglobin A1c; L→Om: Switch from linagliptin to omarigliptin; S→Om: Switch from sitagliptin to omarigliptin; V→Om; Switch from vildagliptin to omarigliptin; SD: Standard deviation.
- Citation: Kawasaki E, Nakano Y, Fukuyama T, Uchida A, Sagara Y, Tamai H, Tojikubo M, Hiromatsu Y, Koga N. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes. World J Diabetes 2021; 12(12): 2087-2095
- URL: https://www.wjgnet.com/1948-9358/full/v12/i12/2087.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i12.2087